59 studies (2 from unattributed sources) on Cagrilintide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Nexaph | 15 | 99.3% | View COA → |
| Shanghai Sigma Audley Ssa | 14 | 98.85% | View COA → |
| Hxnet | 14 | 98.58% | View COA → |
| Wuhan Wansheng Biotechnology | 14 | 98.57% | View COA → |
| GYC | 11 | 99.49% | View COA → |
| Sry Labs | 11 | 99.34% | View COA → |
| Hk Peptides | 8 | 98.75% | View COA → |
| Qingdao Sigma Chemical | 7 | 99.4% | View COA → |
Recent certificates: #14812 (99.908%) · #14477 (89.7%) · #21750 (99.8%) · #14441 (99.04%) · #13492 (99.959%) · #13258 (99.6%)
Manufacturers with published third-party certificates of analysis for Cagrilintide. Open a vendor to see every batch we've verified.
A clinical study is underway to assess how CagriSema, cagrilintide, and semaglutide impact muscle health in overweight individuals with prediabetes during weight loss.
Phase 1 trial to compare Cagrilintide B (with placebo semaglutide I) and Cagrilintide D blood levels in 234 adults with overweight or obesity over 17 weeks.
If successful, cagrilintide could represent a valuable addition to the therapeutic landscape for overweight and obesity, offering a novel mechanism of action through amylin agonism. This Phase 1 trial is critical for …
Optimizing CagriSema dosing could expand treatment options for obesity by identifying regimens that balance efficacy with improved tolerability, potentially leading to broader patient adoption and adherence. Finding e…
This Phase 3 trial is a critical step in evaluating CagriSema as a potentially more potent treatment for obesity and type 2 diabetes than current GLP-1 monotherapies. The large enrollment of 2500 participants and exte…
This Phase 3 study is critical because it directly compares two of the most promising pharmacological approaches for obesity management, potentially establishing a new standard of care. The results will provide invalu…
Understanding the specific metabolic changes induced by CagriSema versus diet-induced weight loss is crucial for optimizing obesity treatment strategies. If CagriSema demonstrates superior or distinct metabolic benefi…
The preservation of bone health during weight loss is a critical consideration, especially for postmenopausal women who are already susceptible to bone density loss and fracture risk. This study is significant because…
The development of CagriSema is significant because it combines two potent mechanisms: Cagrilintide (an amylin analog) and Semaglutide (a GLP-1 receptor agonist), potentially offering synergistic effects for greater w…
The successful completion of enrollment for this Phase 3 trial is a crucial step towards potentially offering a highly effective new treatment option for obesity. If the results demonstrate significant weight loss and…
The successful completion of the REDEFINE 3 trial could have a profound impact on the management of cardiovascular disease, particularly in patients who may also have metabolic comorbidities. If CagriSema demonstrates…
The development of CagriSema represents a significant step towards more effective treatments for Type 2 Diabetes and obesity, conditions that often coexist and exacerbate each other. If the study demonstrates superior…
If the anticipated results confirm strong efficacy and a favorable safety profile, CagriSema could represent a significant advancement in the pharmacological treatment of obesity. By combining two distinct yet complem…
The co-administration of Cagrilintide and Semaglutide represents a potentially significant advancement in the treatment paradigm for Type 2 diabetes. Semaglutide is a GLP-1 receptor agonist known for its glucose-lower…
Effective management of Type 2 Diabetes often requires combination therapies to achieve optimal glycemic control and address comorbidities like obesity. CagriSema combines semaglutide (a potent GLP-1 receptor agonist)…
The potential for CagriSema to offer enhanced weight loss beyond current leading therapies like semaglutide represents a significant advancement in treating obesity. If successful, this combination could provide a mor…
The development of highly effective weight loss medications is crucial for addressing the global obesity epidemic, which contributes to numerous health complications. While individual GIP RAs and amylin agonists show …
The successful demonstration of comparability between different CagriSema delivery devices is a critical step for its future availability and patient accessibility. This Phase 3 study aims to ensure that regardless of…
If CagriSema proves effective, it could represent a significant advancement in managing Chronic Kidney Disease in patients with Type 2 Diabetes and obesity, a population with high unmet medical needs. The potential fo…
If successful, this Phase 3 trial could establish cagrilintide as a highly effective new treatment for obesity and Type 2 Diabetes, offering a significant advancement in weight management. The once-weekly subcutaneous…
These findings are a critical positive step for the continued development of cagrilintide as a potential therapeutic agent for obesity. Demonstrating no significant impact on cardiac repolarisation, a key safety endpo…
This review provides crucial reassurance for both clinicians and patients regarding the thyroid safety profile of GLP-1 RAs, particularly concerning the previously raised concerns about medullary thyroid carcinoma (MT…
This summary highlights the continued global scientific focus on obesity as a multifaceted disease with profound implications for public health. The emphasis on novel therapeutic approaches presented at the WCIRDC sug…
The development of multi-agonist incretin therapies and novel non-incretin pathways represents a critical advancement, offering more potent and comprehensive treatment options for obesity and Type 2 Diabetes than ever…
Understanding how Cagrilintide is processed in individuals with hepatic impairment is a critical step in its development, as it directly informs safe and effective dosing strategies. This pharmacokinetic data will gui…
This study provides compelling evidence that combining cagrilintide and semaglutide offers a highly effective and synergistic therapeutic strategy for achieving substantial and clinically meaningful weight loss, surpa…
The Cagrilintide-Semaglutide combination group demonstrated a remarkable mean body weight reduction of 22.6% from baseline over the 68-week study period, which was statistically significantly superior to all other gro…
This study provides compelling evidence that CagriSema not only facilitates significant weight loss but also directly and substantially improves blood pressure in individuals with overweight or obesity and hypertensio…
This guidance is crucial for plastic surgeons, as it provides a framework to identify and manage nutritional deficiencies that can directly impact the safety and success of body contouring procedures. By understanding…
This research provides a foundational understanding of how amylin receptor agonists are metabolized, which is absolutely critical for preventive doping research. By identifying specific metabolic fingerprints, anti-do…
Treatment with Cagrilintide resulted in profound and statistically significant reductions in body weight and substantial improvements across multiple metabolic markers. > The high-dose Cagrilintide group exhibited a r…
This Phase 3 trial represents a critical step towards providing new, effective treatment options for children and adolescents struggling with overweight and obesity. If successful, the study could establish Cagrilinti…
Understanding the pharmacokinetic equivalence and performance of different CagriSema formulations and delivery devices is crucial for its continued development as a combination therapy for obesity. This study's findin…
If successful, this Phase 3 trial could establish cagrilintide as a novel and effective treatment option for individuals struggling with overweight or obesity. The 64-week duration is designed to demonstrate sustained…
This meta-analysis provides compelling evidence that CagriSema, combining a GLP-1 receptor agonist (semaglutide) with an amylin analog (cagrilintide), offers a substantially more potent and effective treatment option …
While specific pharmacokinetic data (e.g., Cmax, AUC values) are not detailed in this record, the study successfully completed its Phase 1 objectives, enrolling 40 participants and evaluating the drug exposures over a…
The initiation of this Phase 1 trial is a significant step in the development of new treatments for obesity and overweight, conditions with a substantial global health burden. If NNC0174-1213 demonstrates a favorable …
This comprehensive review underscores amylin's critical, yet often underutilized, potential as a therapeutic agent for diabesity. Its unique mechanisms, including appetite suppression and improved glucose regulation, …
This review underscores the critical and enduring role of bariatric surgery as the most efficacious treatment for obesity, even amidst the revolutionary advancements in GLP-1 RA pharmacotherapy. Recognizing the unique…
The development of Amylin-LP1 represents a significant advancement in the therapeutic landscape for metabolic disorders, offering a potent and well-tolerated option. Its long-acting profile could greatly enhance patie…
Free, no account — handy when you're working with Cagrilintide.